FDA nod for gradual resumption at Caraco's US sites
This article was originally published in Scrip
Executive Summary
The US FDA has permitted Sun Pharmaceutical Industries' US arm, Caraco Pharmaceutical Laboratories, to resume operations at its manufacturing facility and packaging sites in Detroit and Wixom, Michigan, though a scale-up at the sites would require product-wise approvals from the regulator.